The Maayan Ventures portfolio firm claims its device saves up to 50% of treatment time.
Maayan Ventures Ltd. (TASE:MAYN) portfolio company ReDent Nova Ltd. has obtained US Food and Drug Administration (FDA) approval for the company's self-adjusting file (SAF) for root canal treatments. ReDent claims that the file presents a new concept of root canal treatment, and that using SAF will save up to 50% of the dentists’ treatment time and reduce recurring treatments and tooth extractions.
The FDA approved the SAF after a successful clinical trial of the device in Israel on over 200 patients, and after ReDent provided the FDA with additional information. ReDent said that, following the FDA approval, together with the earlier EU CE Mark certification of the file, the company will begin marketing of the file in the US and Europe.
Maayan Ventures owns 20% of ReDent.
Published by Globes [online], Israel business news - www.globes-online.com - on January 17, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010